MGI Tech is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries.
Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.
Global leadership in life sciences
MGI fully owns the intellectual property rights of the technologies including DNA Nanoball Sequencing (DNBSEQ™) and Single-Tube Long-Fragment Read (stLFR) library preparation. Over the past decade of innovation and development, MGI’s DNBSEQ technology  has become a trusted platform for cutting-edge research and diagnostics—spanning over 3,900 installations worldwide and contributing to more than 10,000+ peer-reviewed publications. Today, DNBSEQ™ continues to stand at the forefront of sequencing innovation, driving progress in precision medicine, public health, agriculture, biodiversity, and more.
Revolutionizing sequencing technology
Today, MGI offers a comprehensive portfolio of genetic sequencers based on DNBSEQä under T, G, and E series, including the ultra-high-throughput DNBSE²Ï-°Õ20×2 which delivered the world’s first sub-$100 human genome; the widely adopted DNBSEQ-T7 for high-throughput versatility; the ultra-compact DNBSEQ-E25 designed for fieldwork and decentralized testing; the benchtop DNBSEQ-G400;and the fastest in its class for mid-to-low throughput sequencing DNBSEQ-G99; MGI’s newest flagship, the DNBSEQ-T1+, represents the latest evolution of this journey—an ultra-fast benchtop sequencer that balances power, speed, and flexibility. It reflects MGI’s ongoing commitment to continuous innovation, empowering researchers to accelerate discovery without compromise.
A diverse range of sequencing solutions
Innovative products
- DNBSEQ-T7, the ultra-high-throughput sequencer, can produce 1-7Tb of data per day. The cost per Gb sequencing is as low as $5, which marks a new era of the $100 genome.
- DNBSEQ-G400, the comprehensive genetic sequencer DNBSEQ-G400 supports two different chip specifications at one given time. It can accommodate a wider range of applications in scientific research and clinical use.
- DNBSEQ-G99, the latest model of the gene sequencer with mid to low range throughput. Based on MGI’s DNBSEQTMÂ core technology, DNBSEQ-G99 is one of the sequencers with the fastest speed among those with the same throughput in the world.
- DNBSE²Ï-°Õ20×2 is an ultra-high throughput sequencer that can produce up to 50,000 WGS per year while breaking the boundaries to read the sequence of Whole Human Genome for sub $100.
- DNBSEQ-T1+, a next-generation mid-throughput sequencer that completes a paired end 150 sequencing workflow in just 24 hours with Q40 accuracy. With three flow cell formats, two to four addressable lanes on each flow cell, along with dual independent flow cell operation, the DNBSEQ-T1+ provides increased data output with reduced turnaround time which enables increased lab efficiency and flexibility.
Comprehensive support for genomic research
MGI Tech is a leading provider of advanced sequencing and genomic analysis instruments, offering a range of products designed to enhance research and clinical applications in genomics. Their instruments are characterized by high throughput, accuracy, and user-friendly interfaces, catering to various needs in the field of life sciences.
One of their flagship products is the DNBSEQâ„¢ sequencing platform, which utilizes a unique DNA nanoball (DNB) technology. This innovative approach allows for high-density sequencing, resulting in faster data generation and lower costs per base compared to traditional sequencing methods. The DNBSEQâ„¢ platform is versatile, supporting a wide array of applications, including whole-genome sequencing, targeted sequencing, and RNA sequencing, making it suitable for both research and clinical environments.
MGI Tech also offers the MGISEQ series, which includes several models designed for different scales of sequencing projects. These instruments are equipped with advanced optics and fluidics systems, ensuring high-quality data output. The MGISEQ-2000, for instance, is designed for medium to large-scale projects, while the MGISEQ-50 is tailored for smaller applications, providing flexibility for various research needs.
Commitment to innovation and accessibility
In addition to sequencing platforms, MGI Tech provides a range of ancillary products, such as library preparation kits and bioinformatics solutions. Their library preparation kits are optimized for use with their sequencing instruments, ensuring compatibility and efficiency in workflow. The bioinformatics tools offered by MGI Tech facilitate data analysis, enabling researchers to derive meaningful insights from their genomic data quickly.
Another notable product is the MGI’s high-throughput sequencing system, which is designed to meet the demands of large-scale genomic projects. This system integrates automation and advanced software solutions to streamline the sequencing process, significantly reducing the time and labor involved in genomic analysis.
MGI Tech emphasizes the importance of innovation and continuous improvement in their product offerings. They are committed to advancing genomic technologies, making them accessible to a broader range of users, from academic researchers to clinical laboratories. Their focus on quality, efficiency, and user experience positions MGI Tech as a key player in the rapidly evolving field of genomics, contributing to advancements in personalized medicine, disease research, and biotechnology.
